In the present study we show that a prototype vaccine, consisting of a mixture of allogeneic and syngeneic glioma cells and their lysates, administered together with either a multiple TLR2, -4 and -9 agonist BCG [9], or the TLR7/8 agonist resiquimod, is able to inhibit CNS-1 glioma brain tumor growth in syngeneic Lewis rats. Here, TLR2 is linked to glioma.